Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran.
Student Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran.
J Cell Biochem. 2020 Apr;121(4):2739-2755. doi: 10.1002/jcb.29503. Epub 2019 Nov 3.
Innate lymphoid cells (ILCs) as key players in innate immunity have been shown to be significantly associated with inflammation, lymphoid neogenesis, tissue remodeling, mucosal immunity and lately have been considered a remarkable nominee for either tumor-promoting or tumor-inhibiting functions. This dual role of ILCs, which is driven by intrinsic and extrinsic factors like plasticity of ILCs and the tumor microenvironment, respectively, has aroused interest in ILCs subsets in past decade. So far, numerous studies in the cancer field have revealed ILCs to be key players in the initiation, progression and inhibition of tumors, therefore providing valuable insights into therapeutic approaches to utilize the immune system against cancer. Herein, the most recent achievements regarding ILCs subsets including new classifications, their transcription factors, markers, cytokine release and mechanisms that led to either progression or inhibition of many tumors have been evaluated. Additionally, the available data regarding ILCs in most prevalent cancers and new therapeutic approaches are summarized.
先天淋巴细胞 (ILCs) 作为先天免疫的关键参与者，已被证明与炎症、淋巴样新生、组织重塑、黏膜免疫密切相关，最近被认为是具有促进或抑制肿瘤功能的重要候选者。ILCs 的这种双重作用是由内在和外在因素驱动的，分别是 ILCs 的可塑性和肿瘤微环境，这引起了过去十年中对 ILCs 亚群的兴趣。到目前为止，癌症领域的大量研究表明 ILCs 是肿瘤起始、进展和抑制的关键参与者，因此为利用免疫系统对抗癌症的治疗方法提供了有价值的见解。在此，评估了包括新分类、转录因子、标志物、细胞因子释放以及导致许多肿瘤进展或抑制的机制在内的 ILCs 亚群的最新研究成果。此外，还总结了关于最常见癌症中 ILCs 的现有数据和新的治疗方法。
